In This Story
TRFE (TRFE) has submitted its 10-Q filing for the quarterly period ended September 30, 2024.
The filing includes financial statements for the quarter, showing revenues of $9,849 for the three months ended September 30, 2024, compared to $21,457 for the same period in the previous year.
Operating expenses increased to $280,197 for the three months ended September 30, 2024, from $154,061 in the same period of the previous year.
The company reported a net loss of $271,333 for the quarter, compared to a net loss of $172,163 in the previous year.
TRFE experienced a change in control following a merger with Polomar Specialty Pharmacy, resulting in a reverse merger.
The merger led to the acquisition of SlimRx, an online platform for weight loss medications, and the company now operates as a licensed retail compounding pharmacy.
The company is actively seeking approval to provide prescription medications in more U.S. states and anticipates applying for a drug export permit in early 2025.
TRFE's business model includes providing prescription fulfillment services for third-party tele-health platforms.
The company has not generated sufficient revenues to finance its operations internally and is dependent on raising additional capital.
Management plans to raise additional capital and invest in its newly acquired business and other potential opportunities over the next twelve months.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the TRFE quarterly 10-Q report dated November 19, 2024. To report an error, please email earnings@qz.com.